Skip to main content

Wentworth Kory James's Form 4 filing

Entrada Therapeutics, Inc. (TRDA) · filed Dec 3, 2024

Accession no.
0001689375-24-000068
Filed
Dec 3, 2024
Trade date
Nov 29-Dec 2, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $120.0K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Wentworth Kory JamesCIK 0001725663Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 29, 2024Common StockMOption exerciseAcquired+1,000$2.10+$2,10074,849Direct
Nov 29, 2024Common StockSSaleDisposed−1,000$19.97−$19,97073,849Direct
Dec 2, 2024Common StockMOption exerciseAcquired+5,000$2.10+$10,50078,849Direct
Dec 2, 2024Common StockSSaleDisposed−5,000$20.00−$100,00073,849Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 29, 2024Common StockMOption exerciseDisposed−1,000$0.00$036,157Direct
Dec 2, 2024Common StockMOption exerciseDisposed−5,000$0.00$031,157Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)